National Cancer Institute®
Last Modified: February 1, 2002
UI - 11697630
AU - Watanabe J; Kondo H; Hatake K
TI - Autologous stem cell transplantations for recurrent adult T cell leukaemia/lymphoma using highly purified CD34+ cells derived from cryopreserved peripheral blood stem cells.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):1115-7
AD - Division of Clinical Chemotherapy, Cancer Chemotherapy Centre, Japanese Foundation for Cancer Research, Tokyo. firstname.lastname@example.org
We performed double autologous PBSCT in one fulminantly relapsed ATL patient. Cryopreserved PBSCs containing tumour cells were thawed, and CD34+ cells were selected for by immunomagnetic beads, with the aim of decreasing the number of re-infused tumour cells. The patient received 0.72x10(6) and 0.90x10(6) CD34+ cells/kg. The graft contained less than 0.1% T cells. The patient had a very good recovery, and maintained a good quality of life, until she died on Day 339 after her first PBSCT in third relapse. We conclude that autologous PBSCT for ATL patient has benefit in some instances, and cryopreserved PBSCs can be used for CD34+ selection.
UI - 11813173
AU - Little MA; Morland B; Chisholm J; Hole A; Shankar A; Devine T; Easlea D;
TI - Meyer LC; Pinkerton CR A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL.
SO - Med Pediatr Oncol 2002 Feb;38(2):98-103
AD - Royal Marsden Hospital, Sutton, United Kingdom.
BACKGROUND: Despite the current widespread use of prophylactic G-CSF in children with solid tumours and leukaemia, its effectiveness has not been clearly demonstrated. This randomised study evaluates the role of G-CSF given after a 5-day intensification block in children with acute lymphoblastic leukaemia (ALL). PROCEDURE: Forty-six children with ALL or T-Cell non-Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or UKCCSG 9504 NHL protocols were randomised to receive granulocyte colony-stimulating factor following either the first or the second block of intensive chemotherapy in a cross-over study to determine if the prophylactic administration of G-CSF could reduce the rate of readmission to hospital for management of febrile neutropenia. RESULTS: There was a statistically significant difference in the rate of hospital admission in the group receiving prophylaxis, with 34 of 46 being admitted, compared to 42 of 46 patients in the control arm (74 vs. 91%; P=0.0386). There were no differences found in duration of hospital admission, haematological toxicity, neutrophil recovery or duration of supportive care between the two groups. There was no demonstrable cost benefit derived from the prophylactic administration of G-CSF. CONCLUSIONS: This study shows that the prophylactic administration of G-CSF following intensification chemotherapy for childhood ALL and T-NHL produces a significant reduction in the rate of readmission to hospital for the management of febrile neutropenia. Copyright 2002 Wiley-Liss, Inc.
UI - 11734299
AU - Kishino K; Muroi K; Kawano C; Obata T; Sugano N; Nakagi Y; Nagashima T;
TI - Watari K; Iwamoto S; Ozawa K Evaluation of engraftment by ABO genotypic analysis of erythroid burst-forming units after bone marrow transplantation.
SO - Leuk Res 2002 Jan;26(1):13-7
AD - Division of Cell Transplantation and Transfusion, Jichi Medical School, Minamikawachi, 329-0498, Tochigi, Japan.
Six patients received an allogeneic bone marrow transplant from HLA-identical ABO-mismatched donors. ABO genotype of erythroid burst-forming units (BFU-E) from peripheral blood was analyzed using polymerase chain reaction with sequence specific primers (PCR-SSP). After bone marrow transplantation (BMT), engraftment of donor cells by ABO genotypic analysis of BFU-E was compared with ABO phenotypic analysis of red blood cells (RBCs). During the early stage after BMT, ABO genotype of BFU-E in the recipients converted to that of the donors. In contrast, mixed ABO phenotype of RBCs persisted for about 3 months. In one patient, autologous hemopoietic cell recovery was detected by the ABO genotypic analysis before clinical manifestation. ABO genotypic analysis of BFU-E is relevant for enagraftment after ABO-mismatched BMT.
UI - 11426550
AU - White JD; Wharfe G; Stewart DM; Maher VE; Eicher D; Herring B; Derby M;
TI - Jackson-Booth PG; Marshall M; Lucy D; Jain A; Cranston B; Hanchard B; Lee CC; Top LE; Fleisher TA; Nelson DL; Waldmann TA The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.
SO - Leuk Lymphoma 2001 Jan;40(3-4):287-94
AD - Metabolism Branch, National Cancer Institute, University of the West Indies, Kingston, Jamaica.
Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this study was to evaluate the clinical response and toxicity following administration of a combination of IFNalpha-2b and AZT in patients with human T-cell lymphotropic virus type I (HTLV-I)-associated ATL. Eighteen patients with ATL (chronic. crisis, acute or lymphoma type) were treated with the combination of AZT (50 - 200 mg orally 5 times a day) and IFNalpha-2b (2.5 - 10 million units subcutaneously daily). Three patients had objective responses lasting more than one month. One patient had a clinical complete remission, lasting 21.6 months and two patients had partial remissions lasting 3.7 and 26.5 months. Six patients were not considered evaluable for response due to short and/or interrupted periods of treatment. Seventeen patients have died with a median survival time after initiation of therapy of 6 months. Neutropenia and thrombocytopenia were the dose limiting toxicities. In conclusion, the response rate in this study was lower than noted in the two previous published series. This may be due to the amount and type of prior treatment our patients had received.
UI - 11680836
AU - Castagnola E; Zarri D; Caprino D; Losurdo G; Micalizzi C
TI - Cotrimoxazole prophylaxis of Pneumocystis carinii infection during the treatment of childhood acute lymphoblastic leukemia--beware non compliance in older children and adolescents.
SO - Support Care Cancer 2001 Oct;9(7):552-3
AD - Infectious Diseases Unit, G. Gaslini Children's Hospital, Genova, Italy. email@example.com
UI - 11780471
AU - Ma Y; Li Z; Chen G; Dong P; Jiang Y; Zeng Y
TI - Short-term complete remission of a patient with human T lymphotropic virus type-1 associated adult T-cell leukemia/lymphoma with pancytopenia by sequential high-dose methylprednisolone and cyclosporin A.
SO - Chin Med J (Engl) 2001 Apr;114(4):428-30
AD - Department of Hematology, China-Japan Friendship Hospital, Beijing 100029, China.
UI - 11835241
AU - Shimokawa T; Ohashi H; Takaue Y; Kawano Y; Abe T; Kuroda Y
TI - Successful umbilical cord blood transplantation in an infant with ALL failing initial autologous peripheral blood stem cell transplantation.
SO - Med Pediatr Oncol 2002 Jan;38(1):60-1
AD - Department of Pediatrics, National Shikoku Cancer Center Hospital, Matsuyama, Japan. firstname.lastname@example.org
UI - 11835247
AU - Willert JR; Dahl GV; Marina NM
TI - Recurrent mercaptopurine-induced acute pancreatitis: a rare complication of chemotherapy for acute lymphoblastic leukemia in children.
SO - Med Pediatr Oncol 2002 Jan;38(1):73-4
UI - 11838420
AU - Agger KE; Schroder H; Rosthoj S; Carlsen NT; Schmiegelow K
TI - [Trimethoprim-sulfamethoxazole as antibacterial prophylaxis during induction therapy of children with acute lymphatic leukemia]
SO - Ugeskr Laeger 2002 Jan 21;164(4):488-92
AD - Arhus Universitetshospital, Skejby Sygehus, borneonkologisk afdeling, DK-8200 Arhus N.
INTRODUCTION: Children with acute lymphoblastic leukaemia (ALL) are treated with intensive chemotherapy, which results in profound immunosuppression. Treatment with trimethoprim/sulphamethoxazole (TMP-SMX) is therefore used in some departments as prophylaxis against infections with both bacteria and Pneumocystis carinii. The use of TMP/SMX for prophylaxis during the induction therapy is not uniform in the four departments of paediatric oncology in Denmark. This gave us the opportunity to describe the effect of TMP/SMX on bacterial infections in children with ALL during the induction therapy. MATERIAL AND METHODS: with ALL in Denmark. From a retrospective review of the medical charts, the number of children with fever (> 38 degrees C), the number of febrile days, days of antibiotic treatment, and the number of positive blood cultures were registered for each febrile episode. RESULTS: One hundred and fourteen children received TMP/SMX prophylaxis (10-30 mg/SMX/kg/day) and 76 did not. Children who received TMP/SMX prophylaxis had significantly fewer episodes of fever (66/114 (58%) vs. 60/76 (79%), p < 0.01) and significantly fewer children who received the prophylaxis had positive blood cultures before the start of antibiotic treatment compared with children who did not receive prophylaxis (23/114 (20%) vs 37/76 (49%), p < 0.001)). Nineteen different species were isolated from the blood stream before the start of antibiotic treatment. In the non-prophylaxis group there were a preponderance of isolates with Staph. aureus, Str. pneumoniae, E. coli, and P. aeruginosa. There was no difference in the mortality between the two groups (p = 0.44). There were no cases of P. carinii pneumonia in the period of induction therapy. DISCUSSION: TMP/SMX prophylaxis during induction therapy for childhood ALL seems to reduce the risk of bacteraemias and febrile illness.
UI - 11783498
AU - De Abreu RA; Lambooy LH; Ahment K; Brouwer C; Keizer-Garritsen JJ;
TI - Bokkerink JP; Trijbels FJ 6-mercaptopurine: efficacy and bone marrow toxicity in childhood acute lymphoblastic leukemia. Association with low (thio)purine enzyme activity.
SO - Adv Exp Med Biol 2000;486():271-5
AD - Department of Pediatrics, Center for Pediatric Oncology SEN, University Medical Center St Radboud, Nijmegen, The Netherlands.
UI - 11781621
AU - Schneider M; Hettinger K; Matthes-Martin S; Konrad M; Peters C; Gadner
TI - H; Panzer-Grumayer ER Influence of transplantation regimen on prognostic significance of high-level minimal residual disease before allogeneic stem cell transplantation in children with ALL.
SO - Bone Marrow Transplant 2001 Dec;28(11):1087-9
AD - Children's Cancer Research Institute and St Anna Kinderspital, Vienna, Austria.
High MRD levels before transplantation in children receiving T cell-depleted unrelated grafts for relapsed ALL were associated with a 100% relapse risk. We report on two children with relapsed ALL who underwent non T cell-depleted BMT from unrelated donors. Despite a high residual tumor load pre- transplant and the occurrence of only aGVHD grade I, they are still in second complete remission 2.7 and 5.2 years after transplantation, respectively. Thus, we propose that the transplant regimens influence the prognostic significance of high MRD levels pre-BMT.
UI - 11853786
AU - Griffin JD
TI - Resistance to targeted therapy in leukaemia.
SO - Lancet 2002 Feb 9;359(9305):458-9
AD - Leukemia Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA. email@example.com
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.